Latest FDA Biosimilar Nod Pushes Accord Towards 2030 Target

Approval For Filkri Filgrastim Rival To Neupogen Is Latest Milestone

 
• By Dave Wallace
  
Accord Biopharma is targeting 20 biosimilar launches by 2030 (Shutterstock)

More from Biosimilars

More from Products